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INFLUENZA VACCINE GIVEN TO PREGNANT WOMEN REDUCES
HOSPITALIZATION DUE TO INFLUENZA IN THEIR INFANTS
Isaac Benowitz, Daina Esposito, Kristina Gracey, Eugene Shapiro, Marietta Vázquez. Sections of General
Pediatrics and Infectious Diseases, Dept. of Pediatrics, Yale University School of Medicine, New Haven, CT.

The aim of this study was to determine whether giving influenza vaccine to pregnant
women can reduce the incidence of hospitalization due to influenza in their infants in the
first year of life. This was a matched, hospital-based case-control study at Yale-New Haven
Children’s Hospital. Case and control subjects were all aged <12 months at the time of their
hospital admission from 2000 to 2009. All subjects were identified through hospital records.
Cases were infants admitted due to influenza infection. Controls were infants who did not
have influenza infection at the time of hospitalization, matched to cases by date of birth and
date of hospitalization (both within 4 weeks before or after). We contacted parents of all
subjects to collect information on the subjects’ health and home setting and to get
permission to review subjects’ and mothers’ hospital records and outpatient medical
records—this was used to determine whether the subject or mother had received influenza
vaccine or other vaccines and to identify underlying health conditions that could predispose
to severe influenza infection. Conditional logistic regression was used to determine the
relative risk of hospitalization for influenza infection for mothers who did or did not receive
influenza vaccine during pregnancy or other times. The mothers of 2 (2.2%) of 91 cases and
31 (19.9%) of 156 controls aged <6 months and 1 (4.6%) of 22 cases and 2 (5.6%) of 36
controls aged ≥6 months received influenza vaccine during pregnancy. The effectiveness of
influenza vaccine given to mothers in pregnancy in preventing hospitalization in their
infants aged <6 months, adjusted for potential confounders, was 91.5% (95% CI: 61.7%–
98.1%, p=0.001). Influenza vaccine given to pregnant women was 91.5% effective in
preventing hospitalization of their infants due to influenza in the first six months of life.
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INTRODUCTION

Influenza is the leading cause of vaccine-preventable death in the United States (CDC
2003), where it is responsible for 200,000 hospitalizations and 36,000 deaths per year
(Thompson 2004). The highest burden of disease is in young children, pregnant women, the
elderly, and people with certain chronic medical conditions. In young children, the highest
incidence of hospitalization attributable to influenza is in infants aged <1 year, with those
aged <6 months at highest risk (Neuzil 2000). Rates of hospitalization of healthy infants for
influenza are similar to the rates in high risk adults, and are even higher for infants with
underlying chronic medical conditions, in particular respiratory conditions (Neuzil 2000).

Influenza is a respiratory infection caused by the influenza virus that is transmitted through
infected airborne droplets. Common symptoms of infection include fever, headache,
fatigue, dry couch, sore throat, runny or stuff nose, muscle aches, and gastrointestinal upset.
Complications of influenza leading to hospitalization or death can occur from direct effects
of the virus, from exacerbations of pre-existing underlying or chronic medical conditions
such as cardiopulmonary disease, or from causes related to pregnancy or young or old age.
In infants, influenza can present with a sepsis-like picture that differs significantly from the
classic presentation seen in adults. For example, infants may have fever but lack respiratory
symptoms. Gastrointestinal symptoms (such as diarrhea) are another possible presentation.

Influenza is seasonal in the northern hemisphere, predominantly circulating in the fall and
winter months. It typically peaks in February or March, although it may peak as late as
April or May. Influenza virus has circulated in humans for thousands of years; since 1977,
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three influenza virus strains have circulated globally in the human population: A H1N1, A
H3N2, and B. These and other strains also circulate in avian hosts and in other mammals.
Minor strain variation (antigenic drift) occurs from season to season and is associated with
reinfection. Major variation (antigenic shift) occurs less frequently and is associated with
pandemics (Fiore 2009).

In April 2009, a novel influenza strain appeared in the northern hemisphere that was similar
to influenza strains that have circulated in swine in the past but was unlikely any one strain.
This strain, 2009 influenza A H1N1, led to a pandemic with large numbers of people
infected in many countries worldwide, leading to significant morbidity and mortality.

Influenza vaccine

Annual receipt of the influenza vaccine is currently the most effective method of preventing
influenza infection in most individuals and this has been shown to reduce the burden of
influenza infection. Two types of vaccine have been developed and are available
commercially: an injectable, inactivated trivalent vaccine that can be used in any person
aged ≥6 months, and a nasal, live-attenuated vaccine that can be used in non-pregnant,
healthy persons aged 5–49 years. Either vaccine protects recipients against three influenza
virus strains, one from each of the major groups. New influenza vaccine is produced yearly
with the included strains selected several months prior to influenza season to allow for
production, distribution, and administration. This vaccine is 70-90% effective in healthy
adults in a year with good “strain match” between the vaccine strains and the circulating
strains; effectiveness is lower in the elderly and in very young children and in years in
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which there is poor “strain match.” Antiviral medications are also available for the
prevention and treatment of influenza infection; however, these medications currently are
not approved for use in persons aged <12 months (Fiore 2009). No vaccine is available for
use in infants aged <6 months.

Inactivated influenza vaccine is recommended by the Centers for Disease Control and
Prevention (CDC) for all people except for infants aged <6 months (for whom the vaccine
is poorly immunogenic) and persons with a serious allergy to eggs (Fiore 2009, Gruber
1997). Although many influenza infections lead to only minor symptoms, more serious and
life-threatening outcomes are also possible as described above. The recommendation for
annual influenza vaccination is intended to reduce hospitalization and death. Strategies for
the protection of groups who cannot receive influenza vaccine have included washing
hands, avoiding contact with persons infected with influenza, and vaccination of close
contacts (Fiore 2009). Both the CDC and the Advisory Committee for Immunization
Practices recommend that household contacts of infants aged <6 months, along with their
out-of-home caregivers, receive the influenza vaccine in order to form a “cocoon” of
protection. However, the effectiveness of these strategies remains unknown.

CDC and the American College of Obstetrics and Gynecology (ACOG) recommend all
women who will be pregnant during the influenza season receive inactivated influenza
vaccination (Fiore 2008). This recommendation is based on the elevated burden of
influenza-related complications, hospitalization, and death in pregnant women seen during
past influenza seasons and in particular during past influenza pandemics (Fiore 2009,
Naleway 2006). In general, persons aged ≥6 months develop high titers of influenza
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antibodies after vaccination and these antibodies are protective against illness, with the
degree of protection related to the similarity between the strain of influenza in the vaccine
and the strain of influenza circulating in the population at the time of infection. The
antibody response in children at high risk for influenza-related complications might be
lower than that of healthy children (Fiore 2009).

Vaccination of pregnant women could provide protection to the infant early in life, and this
suggests that a novel approach to protect young infants against influenza infection may be
to vaccinate their mothers during pregnancy (Munoz 2001, GPVI 1996). Both animal and
human studies support the possibility of protecting infants against influenza by immunizing
the mother. Antibodies (immunoglobulin G) cross the placenta via active transport from the
mother to the fetus in the final weeks of pregnancy (Kohler 1966, Hobbs 1967, Reuman
1983, Mbawuike 1990). After birth, the infant may receive antibodies (immunoglobulin A)
from the mother via breastmilk (Sweet 1987) and these may provide further protection.

Review of the literature

One study showed that children aged ≤12 months, included those with no previous health
problems, were hospitalized at a rate comparable to that in elderly (Neuzil 2000). Neuzil et
al. also showed that a significant number of annual deaths attributable to influenza infection
occur in infants, and that young children may have a higher risk of influenza-associated
complications and hospitalization compared with healthy older children and adults aged <65
years (Fiore 2009). Complications of influenza infection include bacterial pneumonia,
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dehydration, and worsening of chronic medical conditions such as congestive heart failure,
asthma, and diabetes.

Animal studies have shown that immunizing pregnant mice against influenza protected their
offspring against severe influenza infection. Antibodies are transferred in breastmilk
(immunoglobulin A) and across the placenta (immunoglobulin G) (Reuman 1983,
Mbawuike 1990). In one study, pregnant mice received active influenza vaccine and their
offspring were studied for the response to influenza infection. In another study, pregnant
mice received abdominal (peritoneal) injections of inactivated influenza vaccine and their
offspring, too, were protected against a challenge with a lethal dose of influenza virus
(Mbawuike 1990). Results from both studies indicated that giving influenza vaccine to
pregnant mice significantly decreased the incidence of influenza infection in their offspring.
Both animal studies found that breastfeeding was the primary way that passive antibodies
were transferred to the offspring. Although breastfeeding is thought to be a route of transfer
of antibody from mother to infants, transfer across the placenta is the primordial route in
humans (Sweet 1987).

In humans, maternal antibodies cross the placenta via active transport later during gestation,
presumably around 32 weeks gestation. A study that measured antibody concentration
(immunoglobulin G) in mothers and their infants found higher antibody concentrations in
infants than in mothers, suggesting there is active transport of antibodies across the placenta
(Kohler 1966). Another study measured these antibody levels in 106 premature infants in
the first week of life and found a logarithmic relationship between the level of
immunoglobulin G and gestational age, and suggested that infants born at 32 weeks or
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earlier may have insufficient protection to fight off some infections (Hobbs 1967). No study
has examined total influenza-specific antibodies from mother to the offspring.

Influenza antibodies can also be found in cord blood, indicating presence of such antibodies
at birth, and antibody levels can be studied to determine whether this presence represents
protection from infection. One study of inactivated influenza vaccine in 56 women in the
second and third trimester of gestation found influenza antibodies in 58% of maternal sera
and 42% of infant cord sera, and concluded that a sufficient dose of influenza vaccine given
during pregnancy could form the basis for protection of the infant. The study also suggested
that the timing of delivery relative to the influenza season might be an important
determinant of antibody levels in mothers and their infants (specifically, that delivery
during influenza season may be correlated with higher levels of influenza antibodies in the
infant), that multiple doses of influenza vaccine might be needed in pregnancy to provide
sufficient protection to the infant, and that there was no statistically significant difference
between vaccinating the mother in the second trimester versus vaccinating her in the third
trimester (Sumaya 1979).

Studies have shown that mothers who receive inactivated influenza vaccine during
pregnancy deliver infants who have influenza antibodies that delay the onset and decrease
the severity of influenza infection, with the degree of protection related to the infant’s
influenza antibody level at birth. Women who were naturally infected by influenza also had
infants with similar or higher levels of antibodies (Sumaya 1979; Puck 1980; Reuman 1987;
Englund 1993).
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One study showed that giving influenza vaccine to women during pregnancy resulted in
higher influenza-specific antibody concentrations in infants at birth than in their mothers at
the same point in time, suggesting active transport from mother to infant. That study gave
influenza vaccine to 56 pregnant women in the second or third trimester and monitored
antibody concentrations in 40 mother-infant pairs after birth, and found measurable
antibody titers in several of the infants, even several months after birth. They suggested that
vaccination of pregnant women against influenza could help to protect infants via passive
transfer of maternal antibodies against influenza (Sumaya 1979). Another study measured
transplacental antibodies (immunoglobulin G) to influenza A in stored cord blood of 26
infants who had been brought to primary care facilities and had culture-positive influenza
infection, and found a positive correlation between age at the time of first infection with
influenza and the level of antibody found in cord serum (in other words, infants who had a
higher level of influenza antibody in their cord blood at birth had a later influenza infection
than infants with lower levels of antibody at birth). This suggested that these antibodies are
protective, that vaccinating pregnant women could prevent symptomatic influenza infection
in their infants, that breastfeeding could provide an additional level of protection, and that
the antibody level wanes over time. Infection in the presence of low levels of antibody may
result in attenuated illness (Puck 1980). A third study of influenza antibodies followed
women and their offspring in the United States during an influenza A epidemic in 1979 and
showed that the infants’ concentrations of influenza antibodies at birth correlated with their
mothers’ antibody concentrations. Infants with higher concentrations of influenza
antibodies had a delay in the onset and a decrease in the severity of influenza infection
(Reuman 1987).
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The active transport of antibodies from mother to infant across the placenta occurs in
significant quantities and primarily after 33 weeks gestation, and infants born at an earlier
gestation may be less protected by this immune protection. The presence of maternallyderived antibodies in infancy does not inhibit development of natural immunity later in life
from immunization or natural infection.

There are many reasons to consider maternal vaccination as an effective strategy for the
protection of infants in the first six months of life, including the immature immune systems
in infants of this age and their vulnerability to common bacterial and viral infections, the
adequacy of maternal vaccination, and the cost-effectiveness of giving one dose to the
mother instead of several doses to the infant (Englund 1993, Munoz 2000). Immunizing
women against influenza during pregnancy is a promising strategy for reducing the burden
of influenza-related illness in their infants. Breastfed infants may be further protected by
antibodies (immunoglobulin A) in breast milk (Munoz 2000). Indeed, vaccination of
pregnant women to protect infants against childhood infection is already in widespread
practice for bacterial infections such as tetanus and Haemophilus influenzae Type b, and for
viral diseases such as polio (Munoz 2000). Several vaccines are used in mothers to decrease
the incidence of diseases including pertussis and tetanus in their infants (GPVI 1996).

Inactivated influenza vaccination given to pregnant women has been shown to be safe and
immunogenic in women and their infants (Naleway 2006). However, in spite of data on
safety and the potential benefit to both mother and child, vaccination practices during
pregnancy are poor and vary widely for different healthcare providers and regions: in the
U.S. in 2006, 14% of women got influenza vaccine during pregnancy (CDC 2006). Most
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obstetricians recommend influenza vaccination for pregnant women to protect those women
against severe infection, yet in 2003 only one third of those recommending influenza
vaccination during pregnancy offered this vaccine to their patients (CDC 2005). Studies
have examined the effectiveness of flu vaccination in pregnancy on preventing or
modifying influenza-related morbidity in infants, however their results have been
inconsistent.

Two recent studies compared hospitalizations due to influenza in infants and rates of
influenza-like illness (ILI) or medically attended acute respiratory infection (MAARI) in
infants whose mothers had received influenza vaccination during pregnancy with those
whose mothers had not been vaccinated. Neither study found a protective effect associated
with vaccination during pregnancy; however, both studies included non-influenza infections
along with influenza infections. One study of hospital admissions with principal diagnoses
of influenza or pneumonia and ILI in outpatient visits during five influenza seasons from
1997 to 2002 found that women who received influenza vaccine during pregnancy had the
same risk for ILI visits as unvaccinated women, and their infants had the same risks for
influenza or pneumonia compared with other infants whose mothers had not received the
vaccine (Black 2004). Another study that followed over 41,000 infants for MAARI (another
measure that combines influenza with other diseases such as pneumonia) in outpatient,
emergency department, or inpatient settings, found that maternal influenza vaccination did
not delay the onset of the first respiratory illness (France 2006).

Recently, Zaman et al. conducted a trial of inactivated influenza vaccine given to pregnant
women in Bangladesh found a 63% reduction in laboratory-confirmed influenza illness in
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their infants up to six months old compared with administration of pneumococcal vaccine
(Zaman 2008). This study was conducted outside the US in a region where influenza
infection circulates year-round, unlike the seasonal pattern of influenza seen in the US in
recent decades. Mothers were recruited in the third trimester of pregnancy. This study was
unable to assess effectiveness on hospitalization or severe illness.

Relevance

Influenza infection has significant impacts on society including morbidity and mortality of
infected individuals, impacts on their families, and healthcare utilization and costs, in the
U.S. and worldwide. In children, influenza infection takes on added significance because
there is no vaccine available to protect infants aged <6 months, in contrast to the rest of the
population which can be protected using the vaccine, and these infants are hospitalized for
influenza infection at rates similar to the elderly. Even mild cases of influenza may lead to
lost productivity in society when parents miss work to care for their sick children. Children
are also one of the major routes of spread of influenza in the population. The possibility of a
novel approach to protect infants aged <6 months is of significant importance to the medical
and public health communities. Therefore, proven effectiveness of influenza vaccine given
to pregnant women will have important public health implications worldwide. If
immunizing mothers is found to be effective in providing protection to their infants, this
approach has the potential to improve protection of susceptible infants for whom the
vaccine is not an option until later in life, and it could also further improve on the costeffectiveness of vaccinating pregnant women (Roberts 2006) by protecting two people,
mother and infant, with just one immunization. Results may also increase awareness of the
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importance of influenza vaccination during pregnancy (by protecting women who are
already at high risk for complications from influenza in pregnancy) and it will help
overcome barriers to vaccination, potentially impacting motivations, perceptions, and
attitudes of pregnant women and of their medical providers towards vaccination during
pregnancy.

Statistical power

National surveys in recent years have found that only 13% of pregnant women receive
influenza vaccine (NHIS 2003), with vaccination rates of pregnant women in Connecticut
slightly higher, at around 30% (BRFSS 2005).

Hospital data from our institution showed that approximately 30 infants (aged <12 months)
are admitted with a diagnosis of influenza each year. For this study, we initially anticipated
enrolling 25 cases and 50 matched controls per season (early in the fall through the winter),
a total of 75 subjects per influenza season. We also planned to enroll infants prospectively
over two influenza seasons.

The statistical power to assess the vaccine’s effectiveness depends on the number of
discordant groups (cases and their matched controls), which in turn depends on the rate of
influenza immunization among the mothers of the infants. Assuming that 30% of mothers
are immunized (using the Connecticut data above), enrolling 69 cases would provide 90%
statistical power to detect an effectiveness of the vaccine of 65%. Our plan was to enroll
patients who had been hospitalized during the several years prior to the initiation of our
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study to be able to compare across influenza seasons, and then also to continue enrolling
cases in the hospital setting for two years to be able to collect nasal wash samples.
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HYPOTHESIS
Giving influenza vaccine to women during pregnancy reduces hospitalization of their
infants due to influenza compared to women who did not receive the influenza vaccine
during pregnancy.

AIMS
To assess whether giving influenza vaccine to pregnant women protects their infants against
influenza infection, leading to a lower relative risk of hospitalization before age 12 months.
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METHODS

We conducted a matched case-control study of infants at Yale-New Haven Children’s
Hospital, an academic urban hospital in the northeastern United States.

Eligibility requirements

All subjects were infants aged <12 months, hospitalized at Yale-New Haven Children’s
Hospital due to laboratory-confirmed influenza between 2000 and 2009, prior to the arrival
of the 2009 pandemic influenza A H1N1 in this region. Infants up to age 12 months were be
included because, even though they are potential candidates for influenza vaccine at age 6
months, they may not have received the vaccine and the protective effect of mother’s
antibodies against influenza may still be found.

We excluded infants who were adopted at birth, hospitalized for reasons unrelated to their
respiratory infection (as determined by review of medical records), if their influenza
infection was acquired in the hospital (nosocomial infection), if their mothers had a
contraindication to inactivated influenza vaccine (e.g., egg allergy, prior adverse reaction)
or were unable to consent to participate (e.g., deceased, unknown whereabouts), or if
neither parent could complete the interview in English or Spanish. Infants who received
influenza vaccine at least two weeks prior to hospitalization were excluded, as it would be
impossible to distinguish the effect of vaccination of the mother from the effect of
vaccination of the infant.
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Testing for influenza

Infants hospitalized at this facility with symptoms suggesting a possible infection with a
respiratory virus (including influenza, parainfluenza, and adenovirus) are routinely tested
using a direct fluorescent antibody (DFA) test kit (Light Diagnostics™, Millipore;
Temecula, CA) of a nasal swab sample. This test has been shown to be 96.2% sensitive and
99.0% specific for influenza compared with the polymerase chain reaction technique in our
hospital’s laboratory (Landry 2008). This testing is done for hospital epidemiology (e.g., to
help determine the arrival of influenza in this region and to determine the extent of these
infections in the hospitalized population from week to week) and for patient cohorting (i.e.,
patients with the same respiratory infection may sometimes be placed in a double room
instead of designating two rooms for appropriate contact precautions). The test result is also
available to the clinical team and may be used to guide clinical decision-making.

Identification of potential cases

Cases were infants hospitalized due to influenza with documentation of either a nasal swab
or aspirate that was positive for influenza by DFA as described above. Samples deemed
inadequate by the clinical virology laboratory were not included. Data collection started in
June 2007. Subjects hospitalized between 2000 and May 2007 were identified historically
from the clinical virology laboratory list of all tests for influenza and enrolled by telephone.
During the 2007–2008 and 2008–2009 influenza seasons, research staff identified cases
prospectively by reviewing both clinical virology laboratory list of all tests for influenza
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and the daily list of new hospital admissions to enroll patients in the hospital setting and to
collect a nasal swab sample for further testing.

Selection of controls

For each case, we identified and enrolled two matched controls, who were hospitalized for
reasons other than influenza and who were infants found to be negative for influenza by
DFA. Controls were identified from the same list of all hospitalized patients who had a
DFA test for respiratory viruses and were negative for influenza, matched to cases by date
of birth and date of hospitalization. A patient with a nasal swab sample that tested positive
for another respiratory virus could still be enrolled as a control subject if they were found to
be negative for influenza. Matching started with the subjects born within 2 weeks of the
case (two weeks before or after the case’s date of birth) and who were admitted to the
hospital within 2 weeks of the case (two weeks before or after the case’s date of hospital
admission) and then, if necessary, proceeded to those born within 4 weeks and admitted to
the hospital within 2 weeks from the case, then those born within 2 weeks and admitted to
the hospital within 4 weeks from the case, and finally those born within 4 weeks and
admitted to the hospital within 4 weeks from the case, until two controls were identified.
We used a table of random numbers to determine the order in which to contact potential
eligible subjects within each case-control group. We used risk-set sampling in our selection
of cases and controls: a person could be counted as a control subject multiple times if they
had more than one admission during which they met control criteria, but once a person was
a case (i.e., was hospitalized for influenza) they were no longer eligible to be a control
afterward (Niccolai 2007).
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Collection of data and ascertainment of vaccinations

We conducted interviews with the parents of all study subjects to ask questions pertaining
to demographics, possible confounders such as breastfeeding or susceptible individuals in
the household, and comorbidities of the infant and the mother, and to identify all possible
sources of vaccination of the mother during pregnancy or previously. Interviews were done
in person when a case or control was enrolled prior to hospital discharge, or otherwise by
phone call. All interviews were conducted by study personnel in either English or Spanish.

Information about vaccinations and comorbidities of the infants was obtained by reviewing
medical records from their medical care providers in addition to interview data. We
reviewed the mothers’ medical records from their primary medical providers, obstetricians,
pharmacies, and anywhere the mother stated she would have received influenza vaccine.
We used this information to ascertain whether a mother had received influenza vaccine
during pregnancy, whether she had received the vaccine at any time prior to that pregnancy,
and whether she had received the vaccine during the same influenza season as the infant’s
hospital admission. A mother was considered vaccinated during pregnancy if written
documentation in any record was found indicating receipt of influenza vaccine at least 14
days prior to delivery of the infant.
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Clinical severity of influenza for the cases

We collected clinical data from the infants’ (case subjects’) hospital medical records such as
vital signs suggesting a severe infection (including highest temperature and respiratory rates
and lowest oxygen saturation levels), physical signs of increased work of breathing (such as
retractions or nasal flaring), results of available chest radiographs, and need for mechanical
ventilation and/or admission to the intensive care unit (ICU). We classified the severity of
these symptoms on a scale of 0–16 points, based on our modification of a previouslyvalidated scale of severity of respiratory symptoms in infants with respiratory infections
(Table 1) (Papadopoulos 2002).

Respiratory Specimens

Respiratory samples were collected from case subjects still in the hospital at the time of
enrollment, using the nasal wash technique. RNA was extracted from the clinical specimens
using RNeasy Mini Kit per manufacturer instructions (Qiagen, Valencia, CA). Reverse
transcription and the polymerase chain reaction were performed using primers and
parameters described by the “WHO/CDC Protocol of realtime PCR for influenza A
(H1N1)” (CDC 2009) and the AccessQuick RT-PCR System (Promega, Madison, WI).

Statistical Analysis

We calculated a matched odds ratio for vaccination of mothers of cases compared with
matched controls. The vaccine’s effectiveness was calculated as 1 minus the matched odds
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ratio multiplied by 100. Conditional logistic regression was used to adjust for potential
confounders including race, ethnicity, sex, age, daycare attendance, prematurity,
vaccination of household contacts, breastfeeding, and relevant chronic illness (such as
asthma or reactive airways disease, chronic lung disease, conditions requiring medical
equipment to facilitate breathing, cardiac defects, blood disorders, seizures, metabolic or
endocrine disorders, severe gastrointestinal disease, kidney disease, or spinal cord injury).

A stratified analysis was also conducted to assess for effect modification by age of the
subject (aged ≥6 months vs. aged <6 months) based on the CDC’s recommendation to begin
influenza vaccination at age 6 months and literature suggesting that maternal antibodies
wane at 6–9 months. Whether the subject was identified at the time of hospitalization or
historically via billing data was also evaluated as a possible confounder or effect modifier.

We also assessed the significance of the clinical severity of influenza infection of the cases
using a Student’s t-test or Wilcoxon rank-sum test as appropriate. Analyses were conducted
using SAS® version 9.1.3 for Microsoft (SAS Institute; Cary, NC).
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RESULTS

Enrollment of subjects

We identified a total of 220 eligible case subjects (infants aged <12 months hospitalized due
to influenza) between October 2000 and April 2009. Of the 220 eligible case subjects, 36
(16%) could not be contacted by researchers (for example, because the contact telephone
numbers and addresses were no longer valid). Of the remaining 184 potential case subjects
contacted, parents of 27 (15%) refused to participate (for example, because the parents were
not interested in participating in medical research or they did not feel comfortable releasing
medical records for research purposes), and 157 (85%) were enrolled. Enrollment started in
July 2007. Data presented are from October 2000 and April 2009; data collection is ongoing. Of the 157 enrolled case subjects, 33 (21%) were hospitalized between January 2008
and April 2009 and identified prospectively via active surveillance of laboratory data and
hospital units and 124 (79%) were hospitalized between October 2000 and May 2007 and
identified historically via laboratory data and hospital records; of these, 130 (83%) were
infected with influenza A virus and 27 (17%) with influenza B. For these 157 enrolled
cases, 430 potential matched controls were identified. Of these 430 potential controls, 114
(26.5%) could not be contacted. Of the 316 potential controls that we were able to reach, 45
(14.2%) refused to participate, and 271 (85.8%) were enrolled as controls.

Results presented are for the 113 cases and 192 matched controls (cases with at least one
matched control) in groups with complete data for the case and matched control.
Demographic characteristics of subjects identified prospectively and historically only
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differed statistically significantly on report of sick household members during the month
before hospitalization (59.8% vs. 23.3%, p < 0.001), and length of hospital stay (5.0 ± 13.2
vs. 2.9 ± 3.7 days, p = 0.030).

Subject information and demographics

Characteristics of infants hospitalized with influenza and their matched controls are
presented in Table 2. Cases and matched controls were comparable on most demographic
characteristics and risk factors, as described below and presented in Table 2.

The majority of infants enrolled in the study (80.5% of cases and 81.2% of controls) were
aged <6 months, with slightly more infants aged 0–<3 months (35.4% of cases and 35.9%
of controls) than infants aged 3–<6 months (45.1% of cases and 45.3% of controls) (Table
2). There were roughly equal numbers of male and female infants enrolled as case subjects
(50.4% male and 49.6% female), with slightly more male controls than female controls
(52.6% male and 47.4% female). The majority of cases and controls were white (around
two-thirds of each group), and approximately one-fifth of cases were black and
approximately one-tenth of controls were black, with the remainder in the “other” category.

Cases came from households with a larger number of household members than controls (4.9
± 2.0 vs. 4.4 ± 1.3, p = 0.015), and they were significantly less likely to live with household
members that had received influenza vaccine (32.7% cases vs. 50.0% controls for any
household members vaccinated, and 10.6% cases vs. 15.1% controls for all reported
household members vaccinated with influenza vaccine; p = 0.001). In subjects aged <6
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months, the mothers of 2 (2.2%) of 91 cases and 31 (19.9%) of 156 controls had received
influenza vaccine during pregnancy. In aged ≥6 months, the mothers of 1 (4.6%) of 22
cases and 2 (5.6%) of 36 controls had received influenza vaccine during pregnancy (p =
0.809).

There were no significant demographic differences between mothers who received
influenza vaccine and those who did not receive influenza vaccine (Table 3). In vaccinated
mothers, cases and controls did not differ significantly in the trimester of pregnancy during
which vaccination occurred, with 2 (66.7%) case subjects’ mothers and 26 (78.8%) of the
control subjects’ mothers having received vaccines in the third trimester of pregnancy.

Clinical severity of cases

The median clinical severity scores of the case subjects enrolled was 4 (moderate severity)
on a scale of 0–16 (Figure 1). Case subjects aged ≥6 months at the time of hospitalization
had a significantly higher mean severity score than those aged <6 months (6.3 ± 3.1 vs. 4.1
± 2.7, p = 0.001), and those with chronic medical conditions had higher severity scores than
those without underlying medical conditions (5.3 ± 2.5 vs. 3.5 ± 2.2, p = 0.003). Differences
in clinical severity scores of the cases by mother’s vaccination status during pregnancy were
not statistically significant.
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Respiratory specimens

The nasal samples obtained from the cases identifies prospectively (2007–2009) were all
confirmed to be negative for 2009 pandemic influenza A H1N1. This was evaluated by
comparing the respiratory specimens to known primers for the pandemic influenza strain.

Effectiveness of vaccination

The adjusted effectiveness of the vaccine of 91.5% (95% CI: 61.7%–98.1%, p = 0.001) for
infants aged <6 months, using a final adjusted model that retained immunization of
household contacts (persons other than the subject’s mother residing in the household at the
time of admission) (adjusted odds ratio, 0.420; 95% CI: 0.221–0.798, p = 0.008) and
prematurity (0.375, 95% CI: 0.153–0.918, p = 0.032). The unadjusted effectiveness of
influenza vaccine given to mothers during pregnancy in preventing hospitalization due to
influenza in their infants was 90.7% (95% CI: 59.9%–97.8%, p = 0.001) for this age group.
The effectiveness of the vaccine for infants aged ≥6 months was -41.4% (95% CI: 2257.3%–91.5%, p = 0.809). The effectiveness of the vaccine did not differ significantly
when we compared subjects identified prospectively versus subjects identified historically
(for historically identified subjects, effectiveness: 88.9%, 95% CI: 13.1%–98.6%, p =
0.036; for prospectively identified subjects, effectiveness: 92.0%, 95% CI: 37.0%–99.0%, p
= 0.016; for the Breslow Day test for homogeneity of the odds ratios: p-value = 0.767).
Also, exclusion of subjects born before 32 weeks of gestational age did not significantly
affect the estimate.
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DISCUSSION

Enrollment of subjects

We were able to contact most of the eligible case subjects that we had identified. Reasons
that eligible cases could not be contacted included hospital records that contained only
incorrect or outdated telephone numbers, people who had moved since the time of the
hospitalization and for whom no updated information could be obtained through a search of
hospital data systems, and people who were believed to still live in the same location but
could not be reached by telephone or mail inquiries using all available contact information.

A small number of eligible case subjects and eligible control subjects who were contacted
refused to participate. Although no one single reason predominated this group, some of the
reasons cited included concern about the privacy of their records (e.g., they did not feel
comfortable with someone reviewing the child’s medical records and/or reviewing the
mother’s medical records for reasons unrelated to medical care), disinterest in participating
in medical research, or that they did not want researchers contacting their physicians at all.

Subject information and demographics

A mother’s chance of being offered influenza vaccine during pregnancy is expected to vary
depending on the time of year when the pregnancy begins because the influenza vaccine is
not available year-round, but rather is typically available starting shortly before the arrival
of influenza virus to a region and continuing until at least partway through that season.
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However, we expect that this variability did not differ significantly between cases and
controls because these two groups were closely matched by the infants’ dates of birth.

Clinical severity of cases

The majority of the clinical severity scores were mild to moderate (between 0 and 5 on a
scale of 0–16), with only a handful of cases in the severe range (a score of 6 or greater). The
ranges of clinical severity scores presented in Figure 1 (mild, ≤3; moderate, 4–5; severe, ≥6)
were selected in order to divide the group of cases into roughly equal groups, not based on
prior assumptions regarding a fixed score that would correspond to a clinically valid
severity measure or that would suggest an underlying pathophysiology of disease. Eleven
case subjects (9.7%) were admitted to the ICU.

Effectiveness of vaccination

Our study shows that inactivated influenza vaccine given to pregnant women is highly
effective (91.5%) in preventing hospitalization due to laboratory-confirmed influenza
among their infants aged <6 months. These results have great clinical relevance because
they provide a strategy to confer protection to young infants, a group at high risk for the
disease and for whom no vaccine is currently available. This strategy also has important
public health implications as it would protect not only young infants but also their mothers,
who are also in the high-risk category for severe influenza. Our results on the effectiveness
of this approach in the United States, where influenza is seasonal, are consistent with
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findings in a randomized trial of influenza vaccine in Bangladesh, a tropical developing
country where the pattern and transmission of influenza is perennial (Zaman 2008).

Although there was inadequate statistical power to assess the vaccine’s effectiveness in
infants aged ≥6 months, an estimate of -41.4% with wide confidence intervals indicates that
a null effect in this age group is plausible. This difference in protective effect between
infants aged <6 months (in which a statistically significant protective effect was found) and
infants aged ≥6 months at hospitalization could be explained by the decline of the
concentration of passively transferred antibodies, which one would expect to have dropped
to negligible levels by age 6–9 months and which is supported by earlier work by other
investigators. The interpretation of this effect is, however, complicated by low numbers.

Study limitations

There were several possible limitations to our study. We lacked statistical power to estimate
the effectiveness of influenza vaccine for infants aged ≥6 months. It was also not possible to
assess independently the effects of second versus third trimester vaccination because of
small numbers, however the study is on-going. Women who received influenza vaccine
after birth or in the final two weeks of pregnancy, and who breastfeed their infant for any
period of time, are not expected to transfer influenza antibody across the placenta but they
could still transfer influenza antibody in breastmilk: this effect could not be studied in our
population due to the small number of women receiving influenza vaccine at this time and
the low power to evaluate this question. Furthermore, our study did not have adequate
power to assess the vaccine’s effectiveness by influenza season, allowing us to assess for
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year-to-year variability. Future prospective studies are needed to evaluate longer-term
effectiveness, in subsequent influenza seasons, of this novel strategy.

We have yet to conduct complete laboratory typing of strains to determine whether
influenza infections seen in case subjects were due to strains included in the vaccine or the
degree of mismatch between infecting strains and vaccine strains. We also did not evaluate
seasonal variability for any relationship between infecting strains and common circulating
strains, which could induce immunity in the mothers even in the absence of vaccination.
Further research is needed to evaluate both of these possibilities.

This study includes patients who were hospitalized over nine annual influenza seasons, but
data collection, including surveys given to parents of subjects, began seven years after the
earliest dates of hospitalization in these cases and controls. It is possible that recall bias
could have influenced the ability of mothers to recall information that could not be verified
by the medical record, such as the length of time they breastfed their infants, the number of
other people living in the household and their vaccination status and age, and other
information collected on the survey; we would expect that the reliability of recall for
seasonal influenza vaccination and other information would decrease over successive years.

This study was conducted during years when three influenza virus strains circulated that
were similar to strains that had circulated in the global human population for many decades.
This was prior to the arrival of the 2009 pandemic influenza strain in this region, confirmed
by laboratory analysis of collected nasal wash samples as described above. The pandemic
was considered to have ended by January 2010. CDC anticipates that the pandemic strain
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will circulate along with other strains. It is not known whether the presence of this strain
will change the seasonal pattern of influenza infections or other aspects of the epidemiology
of influenza infections in the United States. The results of this study are not anticipated to
change based on an altered seasonal pattern of influenza or other factors. The possibility
exists that such shifts could alter the effectiveness of this approach, for example by altering
the part of the population that is infected or the age groups that are at highest risk.

Earlier studies found lower degrees of protection associated with influenza vaccination in
the mother compared to our results. The restriction of the case definition to laboratorydocumented influenza infection would be expected to increase the effectiveness of the
maternal vaccination approach. The possibility also exists that our estimate is higher than
the effectiveness in the general population because our controls were infants who were
hospitalized. For example, if mothers of infants in the hospitalized population are less likely
to have received influenza vaccine during pregnancy compared with mothers of infants in
the general population, this could lead to an overestimate of the effectiveness in our study.
Further studies could evaluate this relationship as well as possible connections between a
subject’s socioeconomic status and the likelihood of the mother receiving influenza vaccine.

Study implications

The CDC and the American College of Obstetrics and Gynecology recommend inactivated
influenza vaccination for women who will be pregnant during the influenza season (Fiore
2009) and inactivated influenza vaccination given to pregnant women has been found safe
and immunogenic (Naleway 2006). Despite data on the safety of inactivated influenza
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vaccine for pregnant women and the potential benefit to both mother and infant of this
strategy, rates of vaccination with influenza vaccine in pregnant women are poor and vary
widely for different healthcare providers and regions (CDC 2006). Most obstetricians are
aware of the recommendation for pregnant women to receive influenza vaccination as a
means of protecting women against severe infection. However, in 2003 only one third of
those that recommended influenza vaccination during pregnancy offered this vaccine to
their patients (CDC 2005). In our sample, only 17.2% of mothers of control subjects
received influenza vaccine during pregnancy. It is notable, however, that rates of influenza
vaccination in pregnancy have improved steadily through recent years; 10% controls in
2000-2004, 15% controls in 2005-2007, and 35% controls in 2008-2009 were born to
mothers that had received influenza vaccine during pregnancy, a similar trend to national
data from these years (Fiore 2009).

The public health implications of our findings are important for several reasons. First, they
provide further evidence for a novel, effective strategy for the protection of the infant in the
first six months of life through vaccination of the mother during pregnancy, a novel means
of protecting infants against hospitalization due to influenza and an approach that is not in
widespread use nor widely known among expectant parents concerned about the health of
their infant. Second, many pregnant women currently do not receive influenza vaccine in
pregnancy, and this may also serve as an incentive for those women (who are also at high
risk for complications from influenza) to accept influenza vaccine, and for their providers to
offer it. Hopefully, this evidence could also be used in community and public campaigns to
improve the overall vaccination rates in this high risk group and the degree of protection of
their infants. Also, the use of influenza vaccine in pregnant women has previously been
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found to be cost-effective, and this strategy improves upon that cost-effectiveness (Roberts
2006). Influenza vaccine given to pregnant women is an effective approach to reducing
hospitalization due to influenza in their infants under 6 months old.
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Table 1: Clinical Severity Scale Used to Assess Severity of Influenza
(Mild, 0–3; Moderate, 4–5; Severe, 6–16)
Point Value
Parameter
0
1
2
Heart rate (max # of beats per min)
Age 0-7 days
<130
130-160
>160
Age 1-4 weeks
<135
135-170
>170
Age 1-6 months
<140
140-170
>170
Age 6-12 months
<130
130-160
>160
Respiratory rate (max # of breaths per min)
Age 0-1 month
<50
50-70
>70
Age 1-6 months
<30
30-50
>50
Age 6-12 months
<20
20-40
>40
Oxygen saturation (by pulse oximeter)
≥94%
–
<94%
Wheezing
No
Yes
–
Retractions (intercostal, subcostal, etc.)
No
–
Yes
Nasal Flaring
No
Yes
–
Required intubation/mechanical ventilation
No
–
Yes
Required ICU care
No
–
Yes
Abnormal chest x-ray
No
–
Yes
ICU: intensive care unit
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Table 2: Characteristics of Infants Hospitalized with Influenza and Controls
Characteristic
Age (months)
0–<3
3–<6
6–<9
9–<12
Mean (± standard deviation)
Median
Male gender
Hispanic ethnicity
Race
White
Black
Other
Ever breastfed
Attends daycare
Environmental tobacco smoke
exposure
Premature (gestational age ≤37
weeks)
Gestational age <32 weeks
Gestational age 32-36 weeks
Chronic medical conditions1
Respiratory conditions
Type of residence
Single family home
Multi-family home
Apartment
Other setting2
Mean number of people at home,
including subject, ± standard
deviation; median
Household contacts who had
received influenza vaccine
None
Some
All
1

Cases (%)
(N = 113)

Controls (%)
(N = 192)

P-value
0.998

40 (35.4)
51 (45.1)
12 (10.6)
10 (8.9)
3.2 ± 2.8
2.0
57 (50.4)
45 (39.8)

69 (35.9)
87 (45.3)
19 (9.9)
17 (8.9)
3.1 ± 2.9
2.0
101 (52.6)
59 (30.7)

73 (64.6)
21 (18.6)
19 (16.8)
59 (55.7)
11 (9.8)

129 (67.2)
21 (10.9)
42 (21.9)
115 (67.3)
18 (9.4)

0.052
0.898

35 (31.0)

56 (29.2)

0.739

13 (11.6)

37 (19.3)

0.082

1 (0.9)
12 (10.7)
41 (36.3)
25 (22.1)

10 (3.5)
27 (14.1)
74 (38.5)
25 (24.5)

56 (49.6)
22 (19.5)
31 (27.4)
4 (3.5)

110 (57.3)
26 (13.5)
56 (29.2)
0 (0.0)

4.9 ± 2.1
5.0

4.4 ± 1.3
4.0

0.715
0.106
0.135

0.695
0.640
0.028

0.015
0.001

64 (56.6)
37 (32.7)
12 (10.6)

67 (34.9)
96 (50.0)
29 (15.1)

Includes respiratory conditions (asthma, reactive airways disease, chronic lung disease, and
conditions requiring medical equipment to facilitate breathing) as well as heart defects, blood
disorders, seizures, metabolic or endocrine problems, severe stomach problems, kidney disease,
and spinal cord injuries.
2
Other settings include dormitories, shelters, and mobile homes.
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Table 3: Effectiveness of Influenza Vaccine Given to Mothers During Pregnancy
in Preventing Hospitalization Due to Influenza in their Infants

Mother Vaccinated
Mother Not vaccinated
Unadjusted
Vaccine Effectiveness
[95% CI]
Adjusted1
Vaccine Effectiveness
[95% CI]
1

Subjects aged <6 months
Cases (%) / Controls (%)

Subjects aged ≥6 months
Cases (%) / Controls (%)

2 (2.2) / 31 (19.9)

1 (4.6) / 2 (5.6)

89 (97.8) / 125 (80.1)

21 (95.5) / 34 (94.4)

90.7% [59.9% – 97.8%]
p = 0.001

-41.4% [-2257.3% – 91.5%]
p = 0.809

91.5% [61.7% – 98.1%]
p = 0.001

.

Adjusted model for subjects aged <6 months retained vaccination of household contacts and
prematurity.
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Table 4: Receipt of Influenza Vaccine by Subjects’ Mothers
Cases
(N = 113)
Vaccination status during pregnancy
Not vaccinated
Vaccinated
During hospitalization season
During prior season
For those vaccinated during pregnancy,
timing of vaccination in pregnancy
First trimester
Second trimester
Third trimester
During influenza season when infant was
hospitalized, mother
Not vaccinated
Vaccinated

Controls
(N = 192)

P-value
<0.001

110 (97.4)
3 (2.7)
2 (1.8)
1 (0.9)

159 (82.8)
33 (17.2)
32 (16.7)
1 (0.5)
0.541

0 (0.0)
1 (33.3)
2 (66.7)

0 (0.0)
7 (21.2)
26 (78.8)
<0.001

109 (96.5)
4 (3.5)

155 (80.7)
37 (19.3)
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Figure 1: Clinical Severity Score by Age Group
(p = 0.003)

30

27

Mild (!3)

Number of cases

25

Moderate (4 - 5)

22

Severe ("6)

20

16
13

15
10
5

7

7
4

4
1

6
2

2

0
0 - <3 months
(3.1 ± 1.5)

3 - <6 months
(4.9 ± 3.1)

6 - <9 months
(5.3 ± 2.6)

Age (mean clinical severity score ± std)

9 - <12 months
(7.4 ± 3.5)
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STUDY PERSONNEL

I worked with Dr. Marietta Vázquez and Dr. Eugene Shapiro for the first 18 months of the
study. Dr. Vázquez and Dr. Shapiro provided oversight. I identified case and control
subjects using data from hospital records, made phone calls to enroll participants, and
enrolled cases and controls in the hospital during 2007-2008. In August 2008, Daina
Esposito took over management of this study: she identified case and control subjects,
enrolled additional participants, reviewed records and conducted much of the data analysis.
Kristina Gracey, Nancy Holabird, Marcella Mignosa, Heather Yates, Matthew Burke and
other personnel assisted with enrolling cases and controls, reviewing records, building an
electronic database for results, and other study tasks. RT-PCR analysis of nasal wash
samples was done by Madison Hustedt and Dr. Richard Martinello.
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PATIENT INTERVIEW FORM
INFANT INFORMATION
“First I would like to ask some general questions about [child].”
1.

“What is your relationship to [child]?”
1
Mother/stepmother
2
Father/stepfather
3
Grandparent
4
Other*
*If OTHER, specify:________________________
5
Guardian

2.

“Is [child] Hispanic or Latino?”
1
Yes
0
No
9
Unknown

3.

“Which one or more of the following is [child] race?” (Check all that apply)
1
White
2
Black or African American
3
Asian
4
Native Hawaiian or Other Pacific Islander
5
American Indian or Alaska Native
6
Other*
*Specify: ______________
7
Don’t know/Not sure
9
Declined to answer

4.

“Is [child] an adopted child or living in foster care?”
1
Yes
0
No
9
Unknown

5.

“What was [child]’s birth weight?”
____ lbs ____ozs
(OR)
_________ grams

6.

“Was [child] born early (prematurely)?”
1
Yes
*If YES: “At how many weeks/days was he/she
born?”
0
No
____ weeks +
9
Unknown
____ days

7.

Did [child] have to stay in the hospital more than 4 days after birth?
1
Yes
*If YES, “How many days?”
0
No
____ days
9
Unknown
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8.

“Was [child] ever breastfed?”
Yes*
1*
No
0
Unknown
9
Still BF
11
*IF YES: “How many months old was [child] when all breastfeeding stopped?”___ ___
(# complete months – mark ”99” if unknown)
“For how many weeks was [child] breastfed exclusively?”___ ___
“Next, I am going to ask several questions about a specific period of time. This period
is the 30 days right before your child was hospitalized, which is from __/__/____ to
__/__/____.
I will refer to this as the reference period.” [The reference period begins 30 days prior to
date of admission (or the child’s date of birth, whichever comes later, and ends on the date
of admission.]
“I’d like to begin by asking some general questions about your household during the
reference period that I just mentioned.

9.

“I’m going to read a list of different types of residences. Can you please tell me
which best describes the type of residence in which [child] lived during the
reference period?”
Single family house
1
Duplex or Multi-family house
2
Apartment/Condominium
3
Mobile home/Trailer
4
Dormitory
5
Shelter
6
Other
7
Don’t know/Refuse
9

10.

“So, during the reference period of ______, how many people were living or
staying in this household? Include you, your child, foster children, roomers,
housemates, people staying here that had no other place to stay, long-term visitors,
and people living here most of the time while working, even if they had another
place to live.”
____ ____ (# of people - mark “99” if unknown)

11.

“Please tell me the ages of all the people who lived in the household, including you
but not counting [child] and tell me their relationship to [child]. I would like to
know the ages during the reference period. Please also tell me if each person
smoked at least once during the reference period. Finally, if you recall that any of
these people were sick during the reference period, please let me know that
information, too.”
(record responses in table on next page)
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Note: Please fill out table below for each person living in the house. Circle where appropriate. Do not include
the case/control child. Cigars and pipes should also be included for smoking data.
Relationship codes: 1=mother/stepmother, 2=father/stepfather, 3=sibling, 4=grandparent, 5=aunt/uncle,
6=cousin, 7=friend of family, 8=other.
Relation
to [child]

Age
during
ref.
period

Unit of
age
Years
or
Months

Smoker?
(yes, no,
unknown)

Received seasonal
flu vaccine by end
of ref period?

Received H1N1
flu vaccine by end
of ref period?

Slept in
same room
as child
during ref.
period?

Was
person
sick
during ref.
period?

Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK

Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK

Notes

Type: Nasal (live intra-nasal) IM
(attenuated intra-muscular)
Yr Mo
Yr Mo
Yr Mo
Yr Mo
Yr Mo
Yr Mo
Yr Mo
Yr Mo
Yr Mo

Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK
Yes No
UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Nasal IM No UK

Note: check the total household members against Question 10; clarify any potential
discrepancies
12. “So, during the reference period, there were ____ [count from above] people under
the age of 18 sleeping in the same room as [child]?” (Fix numbers if there is a
discrepancy)
13. “Which best describes the highest level of education that the child’s caretaker has
received?”
No high school
1
Some high school
2
High school graduate/GED
3
Technical school
4
Some college
5
College graduate
6
Post graduate/professional
7
Don’t know/refused
8
14. “Which of the following categories best describes your total household income?”
Up to $15,000
1
$15,000 to $30,000
2
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$30,000 to $45,000
$45,000 to $60,000
More than $60,000
Refused
Don’t know

3
4
5
6
7

“Now, I would like to ask you some questions about [child]’s daycare during the
reference period. The definition of daycare for this evaluation is any setting outside of
your home where your child regularly spent 4 or more hours per week with at least 2
other children of any age under the care of an adult. Include preschool if your child
attended for more than 4 hours/wk. If child care is provided in your home for others,
think of your child as attending day care if care is provided for at least 2 unrelated
children for 4+ hrs/wk with [child].”
15.

“During the reference period, did [child] attend any daycare, as we have just
defined it?” (If child attended >1 daycare, have respondent answer in relation to the
site where the child spent the most time during the week.)
Yes
1
No
0 (Skip to Q. 22)
Unknown
9 (Skip to Q. 22)

16.

“How many hours per week did [child] attend daycare during the reference
period?” (Add total hours per week for all daycare ctrs.)
_______= Total hours/week (mark “999” if unknown)

17.

“For how many months before hospitalization did [child] attend this daycare?” (If
child attended >1 daycare, instruct respondent to answer question in relation to the site
where the child spent the most time during week.)
____ ____ (# months – mark ”99” if unknown, or ”00” if less than 1 month)

18.

“What type of daycare did [child] attend during the reference period? I will read
several options.” (If child attended >1 daycare, instruct respondent to answer in
relation to the site where the child spent the most time during week)
Daycare center*
1*
Preschool*
2*
Home daycare
3
Other
4
Don’t know
9
*If response is either Daycare center (1) or Preschool (2), then also ask Question 19:

19.

“During the reference period, how many children, including [child], were in the
same classroom or daycare setting as [child]?” (If child attended >1 daycare, instruct
respondent to answer in relation to the site where the child spent the most time during
the week)
____ ____
(# of children – mark “99” if unknown)
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20.

During the reference period, how many children, including [child], attended the
same daycare facility as [child]?” (If child attended >1 daycare, instruct respondent
to answer in relation to the site where the child spent the most time during week)
____ ____
(# of children – mark “99” if unknown)

21.

“Were cigarettes smoked inside any facility or home where [child] attended day
care?”
Yes
1
No
0
Unknown
9

“Now I would like to ask you a few questions about [child]’s general health. I will read
a list of health problems. Some terms may be unfamiliar to you because they do not
apply to your family. I will be happy to repeat or explain any terms. I will ask you to
indicate if you were ever told by a physician that [child] had any of these conditions.
Please answer Yes, No, or Don’t know. Answer Yes only if the condition started before
the end of the reference period.”
CASES: “Answer NO if the condition started as part of your child’s influenza
infection.”
CONTROLS: “Answer NO if the condition started as part of your child’s
hospitalization.”
22.

“Sickle cell disease?” (Note: SS or SC disease, not SC trait or being a carrier)
Yes
1
*If YES, specify________________________
No
0
Unknown
9

23.

“Kidney or renal disease?”
Yes*
1*
*If YES, specify type____________________
No
0
Unknown
9
*IF YES: “Does the child require dialysis?”
Yes
1
No
0
Unknown
9

24.

“Heart problems?”
Yes*
1*
No
0
Unknown
9

25.

*If YES, specify type_____________________

“Any chronic problems with the immune system, including any immune system
problem your child was born with?”
Yes
1*
*If YES, specify type_____________________
No
0
Unknown
9
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26.

“Asthma, reactive airways disease, or >1 episode of wheezing?”
Yes*
1*
*If YES, specify type_____________________
No
0
Unknown
9
IF YES: “From birth to hospitalization, how many times did [child] go to the
doctor or emergency room for an attack of asthma, reactive airways disease, or
wheezing?”
__ __ (# of visits – mark “99” if unknown)

27.

“Other chronic lung condition/s?”
Yes*
1* *If YES, please specify type ____________________
No
0
Unknown
9

28.

“A birth defect or chronic condition that makes breathing or swallowing
difficult?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown
9

29.

“A condition that needs medical equipment to make breathing or handling
secretions easier, such as receiving supplemental oxygen, or for which an operation
was done, such as a tracheostomy (a ‘trach’)?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown 9

30.

“Spinal cord injury?”
Yes*
1*
No
0
Unknown
9

31.

*If YES, please specify type____________________

“A seizure disorder or epilepsy?”
Yes*
1*
No
0
Unknown
9
*IF YES: “Are seizures only with fever?”
Yes
1
No*
0*
*If NO, please specify type____________________
Unknown
9

32.

“Severe developmental delay or mental retardation?”
Yes
1*
*If YES, please specify type____________________
No
0
Unknown
9
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33.

“Any neurologic or neuromuscular problems?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown
9

34.

“Any metabolic or endocrine problems?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown
9

35.

“Any serious stomach problems?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown
9

36.

“Any other chronic illnesses?”
Yes*
1*
*If YES, please specify type____________________
No
0
Unknown
9

“Now, I would like to ask you some questions regarding medicines that [child] may
have taken during the reference period.”
37.

“During the reference period, did [child] ever take aspirin for more than a
month?”
Yes
1
No
0
Unknown
9

38.

“During the reference period, did [child] take any steroid medications, such as
Prelone, prednisilone, prednisone, Decadron, dexamethasone or Orapred, either by
mouth as pills or liquid or by injection? These medications are sometimes given for
asthma or other illnesses.” [Note: don’t include inhaled steroids.]
Yes*
1* *If YES: How many days? ___ ____
No
0
Unknown
9

39.

“During the reference period, did [child] use any medications for wheezing,
reactive airways disease, or asthma?”
Yes
1*
*If YES, please specify type____________________
No
0 (Skip to Q. 42)
Unknown
9

40.

“During the reference period, how many different breathing medications did
[child] use on an average day?”
____ # different medications
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41.

“How many doses per day on average did [child] use these medications? For
example, if [child] took two medicines twice a day, that would be 4 doses. Please
include inhaled doses, pills, or liquids taken through a nebulizer.”
Less than 1
0
1 or 2 times
1
3 or more times
2
Don’t know
9

42.

“Did [child’s name] get at least one flu shot?”
Yes
1* *If Yes, number of doses:
No
0
Unknown
9
Child <6 mo
11

1

2

Unknown
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INFORMATION ABOUT THE MOTHER
“Now I want to ask you information about your pregnancy and your health.”
43.

“Did you routinely visit a doctor/healthcare provider while pregnant?” (prenatal
care)
Yes*
1*
No
0
Unknown
9
*If YES: “Approximately how many weeks pregnant were you when you went to
visit a doctor/healthcare provider for the first time?”
_____ weeks

44.

“Did you visit >1 one clinic/office when pregnant, including any other primary
care physicians?” [If you already specifically asked about this during earlier data collection,
skip.]

Yes*
No

1
0

* If YES, record other doctors on the cover page.

45.

“Approx. how many times did you visit the doctor while pregnant?”
Approximate # visits
“Normal” number (1/mo early, 2- 3 visits/month in 3rd trimester)

46.

“Were you ever hospitalized during this pregnancy?”
Yes*
1*
*If YES, explain:______________________________
No
0
______________________________________
______________________________________

47.

“Do you have asthma or chronic obstructive pulmonary disease (COPD)?”
Yes
1*
*If YES, explain:______________________________
No
0
______________________________________
Unknown
9
______________________________________

48.

“Do you have any long-standing/chronic medical problems?”
Yes*
1*
*If YES, explain:______________________________
No
0
______________________________________
Unknown
9
______________________________________

49. “Do you smoke?”
Smoking
details:_________________________
Yes*
1
(past/present) _________________________
No
0
_________________________
(Compare response against data from question 11. This should reflect status at
hospitalization.)
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50. “Did you smoke during the pregnancy?”
Yes
1
No
0
51. “With this child, were you pregnant with more than one child?”
Yes*
1*
If YES, specify: ___________________
No
0
(i.e., twins, triplets)
52. “How many children do you have now (only count live children)?”
____ ____ (# of children – mark “99” if unknown)
53. “Did your doctor/healthcare provider recommend you get flu vaccine when you
were pregnant?”
Yes
1
No
0
Unknown
9
54. “Did you receive influenza vaccine (the flu shot) during this pregnancy?” (check
with response to #11)
Yes*
1* If yes, give details:
________________________________
No
0
(year, location)
________________________________
Unknown
9
________________________________
55. “Other than when you were pregnant, did you EVER receive flu vaccine (before
your child was hospitalized)?” (check with response to #11)
Yes*
1* If yes, give details: ________________________________
No
0 (year, location)
________________________________
Unknown
9
________________________________
56. Have you ever received ANY vaccines (other than the flu shot) outside of your
primary care physician or obstetrician, for example at a pharmacy, at work or at a
public health department?”
Yes*
1* If yes, give details:
________________________________
No
0
(year, location)
________________________________
Unknown
9
________________________________
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HOSPITAL RECORD DATA FORM
Study ID____________________
Checked by: ____ Date checked: _____________
Admission date ____/___/_____
MM/DD/YYYY
DOB ____/___/_____
Age at hospitalization (wks) __________

Sample (check all that apply):
__ Research team; date collected
___/___/_____
__ Leftover sample; date sent
___/___/_____

Reviewer’s initials ____ Date of record review __________
Hospital Medical Record Extraction Form
1. Vitals: Tmax ___C

Axillary

Rectal HRmax ____ RRmax ___ O2Satmin ___ on RA

2. Labs
WBC ________
Diff: ____G ____L ____M ____E ____Bands
DFA _________________
H1N1 PCR___________________
hMPV PCR__________________________
Sputum Culture ______________________
Blood Culture________________________
ABG _______________
CSF results
Culture/gm stain________________________
Cell counts: ____rbc ____nuc cells (___G ____L ___M)
Virology__________________________________________
Urine culture________________________
Other ____________________
3. Wheezing on exam
Yes
No
Not recorded
Nasal flaring on exam
Yes
No
Not recorded
Retractions on exam
Yes
No
Not recorded
Details_______________________________________
4. Imaging
CXR ___________________________________________________
Chest CT _______________________________________________
5. Treatments given for this sickness at PCC, ED and/or hospital
______________________________________________________________
______________________________________________________________
Require 02:
Yes
No If YES, details________________________
6. Diagnoses:_______________________________________________
7. Reasons for admission:_______________________________________________
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8. Hospital admission
8a. If admitted, type:
9. Require ICU care

Yes
Floor
Yes

10. Length hospital stay
11. Intubation
12. Death

No

_____ days

Yes
Yes

No
ICU

No
No

Pre-existing medical conditions/co-morbidities:
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
Also note the presence/absence of these symptoms:

Recording method:

Sneeze
Cough
Rash
Nasal discharge

Yes
Yes
Yes
Yes

No
No
No
No

Unknown
Unknown
Unknown
Unknown

___ Observed by
study personnel
___ Information is
from records

Appearance:

Well

Ill

Toxic

Other pertinent clinical information: (be sure to note recent antibiotic use if any)
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
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RESPIRATORY CLINICAL SEVERITY SCALE
Date: ___/___/___

Time: ___:___ [am/pm]

Scored by: _____ (initials)
0 pts

1 pt

2 pts

Age 0-7 days

<130

130 – 160

>160

Age 1-4 weeks

<135

135 – 170

>170

Age 1-6 months

<140

140 – 170

>170

Age 6-12 months

<130

130 – 160

>160

Age 0-1 month

<50

50 – 70

>70

Age 1-6 months

<30

30 – 50

>50

Age 6-12 months

<20

20 – 40

>40

≥94%

––

<94%

4. Wheezing present?

No

Yes

––

5: Retractions present?

No

––

Yes

6. Nasal flaring present?

No

Yes

––

7. Require intubation?

No

––

Yes

8. Require ICU care?

No

––

Yes

9. Abnormal chest x-ray?

No

––

Yes

1. Heart Rate (max):

______ beats/min

2. Respiratory rate (max): ______ breaths/min

3. Oxygen saturation: ______%

TOTAL SCORE (0-16): ___________
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OUTPATIENT MEDICAL GROUP INFORMATION
Clinic or group:

________________________________________________

Physician(s):

________________________________________________

Address:

____________________ ___________ ____ ________

Phone number:

(____) ____ - ______ (voice) / (____) ____ - ______ (fax)

Type:

Pediatrics
Family
Hospital
Ob/gyn
PMD
L&D
Date of this interview: ______/______/______
Interviewee_____________________________

Other: ________________
Reviewer initials: __ __ __

1. Have you ever given the flu vaccine in this office or in any other office of this
medical group?
Yes
No

If YES, when did you start/stop offering the vaccine? _______________

2. If YES for at least one season:
Do physicians in this office recommend flu vaccine to their patients?
Yes, for children as per CDC recommendations
Yes, for pregnant women as per CDC recommendations
Other: ________________________
No
If the flu vaccine is offered to pregnant women, when is the vaccine administered?
1st trimester
2nd trimester
3rd trimester
How was the vaccination information recorded?
In the patient’s medical records
In the medical group’s billing records
Other: _______________________
How can the vaccination information be obtained?____________________
3. If NO for at least one season:
If a patient had asked for flu vaccine in these seasons, what would have happened?
The patient would have been directed elsewhere: ___________________
We would not have provided any further information or assistance
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OUTPATIENT MEDICAL RECORD REVIEW – INFANT
Subject’s Name:
________________________________________________
Notes about practice__________________________________________ Faxed info:
Type:
Pediatrics
Family
Hospital
Other: ________________
Infant DOB: ______/______/_______
Last time seen: ______/______/______
Admit Date of case/control: ______/______/______
Flu season: ____-____
Date of this record review: ______/______/______
Reviewer initials: _____
Insurance Provider: No___ Yes____ If yes: _____
______ _______________
Public Private
Company
VACCINATION RECORD
DTaP

Prevnar

Dose 1: ____/____/____

Dose 1: ____/____/____

Dose 2: ____/____/____

Dose 2: ____/____/____

Dose 3: ____/____/____

Dose 3: ____/____/____

Dose 4: ____/____/____

Dose 4: ____/____/____

Dose 5: ____/____/____

Pediarix (DTaP, Hep B, IPV)
______________________________
Comvax (HepB and Hib)

Influenza vaccine
Hepatitis B

Common Combination Vaccines
(please circle and add dates)

Dose 1: ____/____/____

______________________________

Dose 1: ____/____/____

Dose 2: ____/____/____

Dose 2: ____/____/____

Dose 3: ____/____/____

Dose 3: ____/____/____

Dose 4: ____/____/____

______________________________

Dose 4: ____/____/____

Dose 5: ____/____/____

ProQuad (MMR + VaricellaMMRV)

Dose 6: ____/____/____
Polio (IPV)

Dose 7: ____/____/____

Dose 1: ____/____/____
Dose 2: ____/____/____

MMR

Dose 3: ____/____/____

Dose 1: ____/____/____

Dose 4: ____/____/____

Dose 2: ____/____/____

Dose 5: ____/____/____

Dose 1: ____/____/____

Dose 1: ____/____/____
Dose 2: ____/____/____

Dose 2: ____/____/____
Dose 3: ____/____/____

Rotateq

Dose 4: ____/____/____

Dose 1: ____/____/____

Dose 5: ____/____/____

Dose 2: ____/____/____

Dose 6: ____/____/____

Dose 3: ____/____/____

Hepatitis A Vaccine

______________________________
Pentacel (DTap, Hib, IPV)
_______________________________
Other vaccine notes:

Varicella Vaccine
Haemophilus influenzae B (Hib)

TriHIBit (DTaP and Hib)

RotaRix

Dose 1: ____/____/____

Dose 1: ____/____/____

Dose 2: ____/____/____

Dose 2: ____/____/____
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(continued)
Date of birth: ____ / ____ / _____ Weeks gestation: ______
Birthweight: ____ lbs ____ oz OR ______ grams
Place of Birth:_______________________________________________________
Child’s other physicians, if listed_________________________________________
Please list all medications and pre-existing medical conditions.
All pre-existing medical conditions:

All chronic or recent medications before acute illness: (route + dose)

Specifics to look for:
 Sickle cell disease
 Kidney/renal disease
 Heart problems
 Chronic immune
problems
 Asthma, reactive
airways disease, or
wheezing
 Birth defects
 Conditions requiring
med equip for
breathing
 Spinal cord injury
 Other chronic
illnesses
 Seizures or epilepsy
 Developmental delay
or mental retardation

Specifics to look for:
Steroid medications
 Prelone, Prednisolone
Prednisone, Decadron,
Dexamethasone,
Orapred
Medications
 Albuterol
 Aspirin (long term)
Be sure to include the
type, route and dose for
all medications listed
here.

Acute illness – brief history
# visits to clinic or practice for acute illness ___

Other pertinent information noted in medical record:
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OUTPATIENT MEDICAL RECORD REVIEW – MOTHER
Reviewer initials: __ __

Date of record review:

______/______/______
Any other physicians listed
______________________________________________________
Where child was
delivered_______________________________________________________
Date of birth: ____ / ____ / _____

Date of admission: ____ / ____ / _____

Birth weight: ______ (circle: lb/oz grams)

Weeks gestation: ______

Insurance Provider: No___ Yes____ If yes: ____
(0)
(1)
Public

_____
Private

________________
Name of Company

Mother received flu vaccine at this practice?
Yes, dose 1 date: ____ / ____ / ____Type:

TIV inactivated

LAIV, live, attenuated

Yes, dose 2 date:____ / ____ / ____Type:

TIV, inactivated

LAIV, live, attenuated

Yes, dose 3 date:____ / ____ / ____Type:

TIV, inactivated

LAIV, live, attenuated

Yes, dose 4 date:____ / ____ / ____Type:

TIV, inactivated

LAIV, live, attenuated

No If no, provide reason:

Offered at practice, but declined

Other

reason__________
Unknown/no information available
Received flu vaccine during pregnancy?

Received flu vaccine during season

above?
(0) No

(0) No

(1) Yes, during season of admission

(1) Yes, during pregnancy

(2) Yes, during last flu season

(2) Yes, after delivery

(9) Unknown

(3) Yes, pregnancy was last season
(9) Unknown

Other vaccines:
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(continued)
Any prior long-standing/chronic medical problems: (i.e. asthma, COPD, diabetes)
Yes

No

Unknown/no information available

Any medications?
Yes
No
Unknown/no information available

Any complications during this pregnancy: (especially conditions requiring
hospitalization)
Yes
No
Unknown/no information available

Did mom ever smoke?
Yes
No
Unknown/no information available
If YES, details
Other information:

